Biohaven Sets the Stage with a $225 Million Public Offering: What Lies Ahead?
Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies for a wide range of rare and common … Read more